
CLAIMS

1. A compound of general formula (I) :




(I)

in which :

R^1 represents $-(CH_2)_n-(CHR^4)-(CH_2)_m-N(R^5)(R^{5'})$;

R^2 represents a heteroaryl of structure :



in which :

* represents the point of attachment of said heteroaryl with the rest of the structure of general formula (I) ;

R^3 is methyl ;

R^4 is hydroxy ;

R^5 and $R^{5'}$ are the same or different and are, independently of each other, a hydrogen atom, or a C_1-C_6-alkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, or C_1-C_6-alkoxy-C_1-C_6-alkyl,

or

R^5 and $R^{5'}$, taken together with the nitrogen atom to which they are bound,

represent a 3- to 7-membered nitrogen containing heterocyclic ring optionally containing at least one additional heteroatom selected from oxygen, nitrogen or sulfur and which may be optionally substituted with 1 or more $R^{6'}$ groups ;

each occurrence of R^6 may be the same or different and is independently a hydrogen atom, a halogen atom, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, aryl, aryl-C_1-C_6-alkyl, heteroaryl, heteroaryl-C_1-C_6-alkyl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-C_1-C_6-alkyl, -C_1-C_6-alkyl-OR^7, -C_1-C_6-alkyl-SR^7, -C_1-C_6-alkyl-$N(R^7)(R^{7'})$, -C_1-C_6-alkyl-$C(=O)R^7$,-CN, $-C(=O)OR^7$, $-C(=O)N(R^7)(R^{7'})$, $-OR^7$, $-SR^7$, $-N(R^7)(R^{7'})$, or $-NR^7C(=O)R^7$ each of which may be optionally substituted with 1 or more R^8 groups ;

each occurrence of $R^{6'}$ may be the same or different and is independently C_1-C_6-alkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, or C_1-C_6-alkyl-OR^7;


each occurrence of R^7 and $R^{7'}$ may be the same or different and is independently a hydrogen atom, or a C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_6-alklyl, C_3-C_6-cycloalkenyl, aryl, aryl-C_1-C_6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-C_1-C_6-alkyl, or heteroaryl-C_1-C_6-alkyl ;

each occurrence of R^8 is independently a halogen atom, or nitro, hydroxy, cyano, formyl, acetyl, amino, C_1-C_6-alkyl, C_1-C_6-alkoxy, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, C_1-C_6-cycloalkenyl, aryl, aryl-C_1-C_6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, heterocyclyl-C_1-C_6-alkyl, or heteroaryl-C_1-C_6-alkyl ;

n is an integer of 1 and m is an integer of 1 ;

with the proviso that when :


- said R^5 and $R^{5'}$, taken together with the nitrogen atom to which they are bound, represent :




in which * represents the point of attachment with the rest of the structure of general formula (I),

then

- said R^2 heteroaryl of structure :



is not :




in which * represents the point of attachment with the rest of the structure of general formula (I).

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same.

2. The compound according to claim 1, wherein :

R^1 represents $-(CH_2)_n-(CHR^4)-(CH_2)_m-N(R^5)(R^{5'})$;

R^2 represents a heteroaryl of structure :



in which :

* represents the point of attachment of said heteroaryl with the rest of the structure of general formula (I) ;

R^3 is methyl ;

R^4 is hydroxy ;

R^5 and $R^{5'}$ are the same or different and are, independently of each other, a hydrogen atom, or a C_1-C_6-alkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, or C_1-C_6-alkoxy-C_1-C_6-alkyl,

or

R^5 and $R^{5'}$, taken together with the nitrogen atom to which they are bound, represent a 3- to 7-membered nitrogen containing heterocyclic ring optionally containing at least one additional heteroatom selected from oxygen, or nitrogen ~~or sulfur~~ and which may be optionally substituted with 1 or more $R^{6'}$ groups ;

each occurrence of R^6 may be the same or different and is independently a hydrogen atom, a halogen atom, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, aryl, aryl-C_1-C_6-alkyl, heteroaryl, heteroaryl-C_1-C_6-alkyl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-C_1-C_6-alkyl, -C_1-C_6-alkyl-OR^7, -C_1-C_6-alkyl-SR^7, -C_1-C_6-alkyl-$N(R^7)(R^{7'})$, -C_1-C_6-alkyl-$C(=O)R^7$,-CN, $-C(=O)OR^7$, $-C(=O)N(R^7)(R^{7'})$, $-OR^7$, $-SR^7$, $-N(R^7)(R^{7'})$, or $-NR^7C(=O)R^7$ each of which may be optionally substituted with 1 or more R^8 groups ;

each occurrence of $R^{6'}$ may be the same or different and is independently C_1-C_6-alkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, or C_1-C_6-alkyl-OR^7;


each occurrence of R^7 and $R^{7'}$ may be the same or different and is independently a hydrogen atom, or a C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_6-alklyl, C_3-C_6-cycloalkenyl, aryl, aryl-C_1-C_6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-C_1-C_6-alkyl, or heteroaryl-C_1-C_6-alkyl ;

each occurrence of R^8 is independently a halogen atom, or nitro, hydroxy, cyano, formyl, acetyl, amino, C_1-C_6-alkyl, C_1-C_6-alkoxy, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, C_1-C_6-cycloalkenyl, aryl, aryl-C_1-C_6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, heterocyclyl-C_1-C_6-alkyl, or heteroaryl-C_1-C_6-alkyl ;

n is an integer of 1 and m is an integer of 1 ;

with the proviso that when :


- said R^5 and $R^{5'}$, taken together with the nitrogen atom to which they are bound, represent :




in which * represents the point of attachment with the rest of the structure of general formula (I),

then

- said R^2 heteroaryl of structure :



is not :



in which * represents the point of attachment with the rest of the structure of general formula (I)

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same.

3. The compound according to any one of claims 1, or claim 2, which is selected from the group consisting of :

N-(8-{[(2R)-2-hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2S)-2-hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-[8-({(2R)-3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-hydroxypropyl}oxy)-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2R)-3-(azetidin-1-yl)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(piperidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-{8-[3-(dimethylamino)-2-hydroxypropoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyridine-3-carboxamide

N-(8-{[(2R)-3-(dimethylamino)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2R)-3-(dipropan-2-ylamino)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide

N-(8-{[(2R)-3-(azetidin-1-yl)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide

N-[8-({(2R)-3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-

hydroxypropyl}oxy)-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]-2-methylpyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(piperidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide

N-(8-{[(2R)-3-(dipropan-2-ylamino)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide

6-amino-N-(8-{[(2R)-2-hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide

2-amino-N-[8-({(2R)-3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-hydroxypropyl}oxy)-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide

2-amino-N-(8-{[(2R)-2-hydroxy-3-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide dihydrochloride

2-amino-N-(8-{[(2R)-3-(dimethylamino)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-thiazole-5-carboxamide

N-[8-({(2R)-3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-hydroxypropyl}oxy)-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]-1,3-thiazole-5-carboxamide

N-(8-{[(2R)-3-(azetidin-1-yl)-2-hydroxypropyl]oxy}-7-methoxy-2,3-

dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-thiazole-5-carboxamide
N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-thiazole-5-carboxamide
N-(8-{[(2R)-2-hydroxy-3-(piperidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-thiazole-5-carboxamide
N-(8-{[(2R)-2-Hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-4-methyl-1,3-thiazole-5-carboxamide
2-amino-N-(8-{[(2R)-2-hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-4-methyl-1,3-thiazole-5-carboxamide
N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-oxazole-5-carboxamide
N-(8-{[(2R)-3-(dipropan-2-ylamino)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-thiazole-5-carboxamide
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or mixture of the same.

4. The compound according to any one of claims 1, 2, or 3, which is selected from the group consisting of :

N-(8-{[(2R)-2-hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide
N-[8-({(2R)-3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-hydroxypropyl}oxy)-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyridine-3-carboxamide
N-(8-{[(2R)-2-hydroxy-3-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide
N-(8-{[(2R)-3-(azetidin-1-yl)-2-hydroxypropyl]oxy}-7-methoxy-2,3-

dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide
N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide
N-(8-{[(2R)-2-hydroxy-3-(piperidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide
N-(8-{[(2R)-3-(dimethylamino)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide
N-(8-{[(2R)-3-(dipropan-2-ylamino)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide
N-(8-{[(2R)-2-hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide
N-(8-{[(2R)-3-(azetidin-1-yl)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide
N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide
N-(8-{[(2R)-2-hydroxy-3-(piperidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide
N-(8-{[(2R)-3-(dipropan-2-ylamino)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide
N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide
N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-thiazole-5-carboxamide
N-(8-{[(2R)-2-hydroxy-3-(piperidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-thiazole-5-carboxamide
N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-

dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-oxazole-5-carboxamide or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or mixture of the same.

5. The compound according to claim 1 or claim 2, wherein :
R^5 and $R^{5'}$, taken together with the nitrogen atom to which they are bound, represent a 3- to 7-membered nitrogen containing heterocyclic ring optionally containing at least one additional heteroatom selected from oxygen or nitrogen and which may be optionally substituted with 1 or more $R^{6'}$ groups , or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same.

6. The compound according to claim 1 or claim 2, wherein :
R^5 and $R^{5'}$, taken together with the nitrogen atom to which they are bound, represent morpholinyl,
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same.

7. The compound according to claim 1 or claim 2, wherein :
R^6 is C_1-C_6-alkyl, preferably C_1-C_3-alkyl, which may be optionally substituted with 1 or more R^8 groups,
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same.

8. The compound according to claim 1 or claim 2, wherein :
each occurrence of R^6 may be the same or different and is independently a hydrogen atom, a halogen atom, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, aryl, aryl-C_1-C_6-alkyl, heteroaryl, heteroaryl-C_1-C_6-alkyl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-C_1-C_6-alkyl, -C_1-C_6-alkyl-OR^7, -C_1-C_6-alkyl-SR^7, -C_1-C_6-alkyl-

$N(R^7)(R^{7'})$, $-C_1$-C_6-alkyl-$C(=O)R^7$,-CN, $-C(=O)OR^7$, $-C(=O)N(R^7)(R^{7'})$, $-OR^7$, $-SR^7$, or $-NR^7C(=O)R^7$ each of which may be optionally substituted with 1 or more R^8 groups,


or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same.

9. The compound according to claim 1 or claim 2, which is N-(8-{[(2R)-2-Hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same.

10. The compound according to claim 1 or claim 2, which is N-(8-{[(2R)-2-Hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide or a physiologically acceptable salt, or a mixture of same.

11. The compound according to claim 1 or claim 2, which is N-(8-{[(2R)-2-Hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide.

12. A method of preparing a compound of general formula (I) according to any one of claims 1 to 11, said method comprising the step of allowing an intermediate compound of general formula (XI) :



(XI)


in which R1 and R3 are as defined for general formula (I) in any one of claims 1 to 11,

to react with a compound of general formula (XIa) :

R^2COOH

(XIa),

in which R2 is as defined for general formula (I) in any one of claims 1 to 11, thereby giving a compound of general formula (I) :



(I)

in which R^1, R^2 and R^3 are as defined for general formula (I) in any one of claims 1 to 11.

13. A compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 11, for use in the treatment or prophylaxis of a disease.

14. A pharmaceutical composition comprising a compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 11, and a pharmaceutically acceptable diluent or carrier.

15. A pharmaceutical combination comprising :

- one or more compounds of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 11 ;

and


- one or more agents selected from : a taxane, such as Docetaxel, Paclitaxel, or Taxol; an epothilone, such as Ixabepilone, Patupilone, or Sagopilone; Mitoxantrone; Predinisolone; Dexamethasone; Estramustin; Vinblastin; Vincristin; Doxorubicin; Adriamycin; Idarubicin; Daunorubicin; Bleomycin; Etoposide; Cyclophosphamide; Ifosfamide; Procarbazine; Melphalan; 5-Fluorouracil; Capecitabine; Fludarabine; Cytarabine; Ara-C; 2-Chloro-2´-deoxyadenosine; Thioguanine; an anti-androgen, such as Flutamide, Cyproterone acetate, or Bicalutamide; Bortezomib; a platinum derivative, such as Cisplatin, or Carboplatin; Chlorambucil; Methotrexate; and Rituximab.

16. A compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 11, for use in therapy.

17. Use of a compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 11, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of uncontrolled cell growth, proliferation and/or survival, an inappropriate cellular immune response, or an inappropriate cellular inflammatory response, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is mediated by the phosphotidylinositol-3-kinase (PI3K) pathway, more particularly in which

the disease of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is a haemotological tumour, a solid tumour and/or metastases thereof, *e.g.* leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.

18. A compound of general formula (XI) :




(XI)

in which R1 and R3 are as defined for general formula (I) in any one of claims 1 to 11.

19. Use of compounds of general formula (XI) according to claim 18, for the preparation of a compound of general formula (I) according to any one of claims 1 to 11.

CLAIMS

1. A compound of general formula (I) :




(I)

in which :

R^1 represents $-(CH_2)_n-(CHR^4)-(CH_2)_m-N(R^5)(R^{5'})$;

R^2 represents a heteroaryl of structure :



in which :

* represents the point of attachment of said heteroaryl with the rest of the structure of general formula (I) ;

R^3 is methyl ;

R^4 is hydroxy ;

R^5 and $R^{5'}$ are the same or different and are, independently of each other, a hydrogen atom, or a C_1-C_6-alkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, or C_1-C_6-alkoxy-C_1-C_6-alkyl,

or

R^5 and $R^{5'}$, taken together with the nitrogen atom to which they are bound,

represent a 3- to 7-membered nitrogen containing heterocyclic ring optionally containing at least one additional heteroatom selected from oxygen, nitrogen or sulfur and which may be optionally substituted with 1 or more $R^{6'}$ groups ;

each occurrence of R^6 may be the same or different and is independently a hydrogen atom, a halogen atom, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, aryl, aryl-C_1-C_6-alkyl, heteroaryl, heteroaryl-C_1-C_6-alkyl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-C_1-C_6-alkyl, -C_1-C_6-alkyl-OR^7, -C_1-C_6-alkyl-SR^7, -C_1-C_6-alkyl-$N(R^7)(R^{7'})$, -C_1-C_6-alkyl-$C(=O)R^7$,-CN, -$C(=O)OR^7$, -$C(=O)N(R^7)(R^{7'})$, -OR^7, -SR^7, -$N(R^7)(R^{7'})$, or -$NR^7C(=O)R^7$ each of which may be optionally substituted with 1 or more R^8 groups ;

each occurrence of $R^{6'}$ may be the same or different and is independently C_1-C_6-alkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, or C_1-C_6-alkyl-OR^7;


each occurrence of R^7 and $R^{7'}$ may be the same or different and is independently a hydrogen atom, or a C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_6-alklyl, C_3-C_6-cycloalkenyl, aryl, aryl-C_1-C_6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-C_1-C_6-alkyl, or heteroaryl-C_1-C_6-alkyl ;

each occurrence of R^8 is independently a halogen atom, or nitro, hydroxy, cyano, formyl, acetyl, amino, C_1-C_6-alkyl, C_1-C_6-alkoxy, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, C_1-C_6-cycloalkenyl, aryl, aryl-C_1-C_6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, heterocyclyl-C_1-C_6-alkyl, or heteroaryl-C_1-C_6-alkyl ;

n is an integer of 1 and m is an integer of 1 ;

with the proviso that when :


- said R^5 and $R^{5'}$, taken together with the nitrogen atom to which they are bound, represent :



in which * represents the point of attachment with the rest of the structure of general formula (I),

then

R^2 is not :




in which * represents the point of attachment with the rest of the structure of general formula (I),

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same.

2. The compound according to claim 1, wherein :

R^1 represents $-(CH_2)_n-(CHR^4)-(CH_2)_m-N(R^5)(R^{5'})$;

R^2 represents a heteroaryl of structure :



in which :

* represents the point of attachment of said heteroaryl with the rest of the structure of general formula (I) ;

R^3 is methyl ;

R^4 is hydroxy ;

R^5 and $R^{5'}$ are the same or different and are, independently of each other, a hydrogen atom, or a C_1-C_6-alkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, or C_1-C_6-alkoxy-C_1-C_6-alkyl,

or

R^5 and $R^{5'}$, taken together with the nitrogen atom to which they are bound, represent a 3- to 7-membered nitrogen containing heterocyclic ring optionally containing at least one additional heteroatom selected from oxygen or nitrogen and which may be optionally substituted with 1 or more $R^{6'}$ groups ;

each occurrence of R^6 may be the same or different and is independently a hydrogen atom, a halogen atom, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, aryl, aryl-C_1-C_6-alkyl, heteroaryl, heteroaryl-C_1-C_6-alkyl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-C_1-C_6-alkyl, -C_1-C_6-alkyl-OR^7, -C_1-C_6-alkyl-SR^7, -C_1-C_6-alkyl-$N(R^7)(R^{7'})$, -C_1-C_6-alkyl-$C(=O)R^7$,-CN, -$C(=O)OR^7$, -$C(=O)N(R^7)(R^{7'})$, -OR^7, -SR^7, -$N(R^7)(R^{7'})$, or -$NR^7C(=O)R^7$ each of which may be optionally substituted with 1 or more R^8 groups ;

each occurrence of $R^{6'}$ may be the same or different and is independently C_1-C_6-alkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, or C_1-C_6-alkyl-OR^7;

each occurrence of R^7 and $R^{7'}$ may be the same or different and is independently a hydrogen atom, or a C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_6-alklyl, C_3-C_6-cycloalkenyl, aryl, aryl-C_1-C_6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-C_1-C_6-alkyl, or heteroaryl-C_1-C_6-alkyl ;


each occurrence of R^8 is independently a halogen atom, or nitro, hydroxy, cyano, formyl, acetyl, amino, C_1-C_6-alkyl, C_1-C_6-alkoxy, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, C_1-C_6-cycloalkenyl, aryl,

aryl-C_1-C_6-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, heterocyclyl-C_1-C_6-alkyl, or heteroaryl-C_1-C_6-alkyl ;

n is an integer of 1 and m is an integer of 1 ;

with the proviso that when :


- said R^5 and $R^{5'}$, taken together with the nitrogen atom to which they are bound, represent :



in which * represents the point of attachment with the rest of the structure of general formula (I),

then

. R^2 is not :



in which * represents the point of attachment with the rest of the structure of general formula (I)

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same.

3. A compound which is selected from the group consisting of :

N-(8-{[(2R)-2-hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2S)-2-hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-[8-({(2R)-3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-hydroxypropyl}oxy)-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2R)-3-(azetidin-1-yl)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(piperidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-{8-[3-(dimethylamino)-2-hydroxypropoxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyridine-3-carboxamide

N-(8-{[(2R)-3-(dimethylamino)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2R)-3-(dipropan-2-ylamino)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide

N-(8-{[(2R)-3-(azetidin-1-yl)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide

N-[8-({(2R)-3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-hydroxypropyl}oxy)-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]-2-methylpyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(piperidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide

N-(8-{[(2R)-3-(dipropan-2-ylamino)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide

6-amino-N-(8-{[(2R)-2-hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide

2-amino-N-[8-({(2R)-3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-hydroxypropyl}oxy)-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide

2-amino-N-(8-{[(2R)-2-hydroxy-3-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide dihydrochloride

2-amino-N-(8-{[(2R)-3-(dimethylamino)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-thiazole-5-carboxamide

N-[8-({(2R)-3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-hydroxypropyl}oxy)-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]-1,3-thiazole-5-carboxamide

N-(8-{[(2R)-3-(azetidin-1-yl)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-thiazole-5-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-thiazole-5-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(piperidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-thiazole-5-carboxamide

N-(8-{[(2R)-2-Hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-4-methyl-1,3-thiazole-5-carboxamide

2-amino-N-(8-{[(2R)-2-hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-4-methyl-1,3-thiazole-5-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-oxazole-5-carboxamide

N-(8-{[(2R)-3-(dipropan-2-ylamino)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-thiazole-5-carboxamide

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or mixture of the same.

4. The compound according to claim 3, which is selected from the group consisting of :

N-(8-{[(2R)-2-hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-[8-({(2R)-3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-hydroxypropyl}oxy)-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2R)-3-(azetidin-1-yl)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(piperidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2R)-3-(dimethylamino)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2R)-3-(dipropan-2-ylamino)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide

N-(8-{[(2R)-3-(azetidin-1-yl)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(piperidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide

N-(8-{[(2R)-3-(dipropan-2-ylamino)-2-hydroxypropyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-thiazole-5-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(piperidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-thiazole-5-carboxamide

N-(8-{[(2R)-2-hydroxy-3-(pyrrolidin-1-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1,3-oxazole-5-carboxamide

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or mixture of the same.

5. The compound according to claim 1 or claim 2, wherein :

R^5 and $R^{5'}$, taken together with the nitrogen atom to which they are bound, represent a 3- to 7-membered nitrogen containing heterocyclic ring optionally

containing at least one additional heteroatom selected from oxygen or nitrogen and which may be optionally substituted with 1 or more $R^{6'}$ groups , or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same.

6. The compound according to claim 1 or claim 2, wherein :
R^5 and $R^{5'}$, taken together with the nitrogen atom to which they are bound, represent morpholinyl,
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same.

7. The compound according to claim 1 or claim 2, wherein :
R^6 is C_1-C_6-alkyl, preferably C_1-C_3-alkyl, which may be optionally substituted with 1 or more R^8 groups,
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same.

8. The compound according to claim 1 or claim 2, wherein :
each occurrence of R^6 may be the same or different and is independently a hydrogen atom, a halogen atom, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_3-C_6-cycloalkyl, C_3-C_6-cycloalkyl-C_1-C_6-alkyl, aryl, aryl-C_1-C_6-alkyl, heteroaryl, heteroaryl-C_1-C_6-alkyl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-C_1-C_6-alkyl, -C_1-C_6-alkyl-OR^7, -C_1-C_6-alkyl-SR^7, -C_1-C_6-alkyl-$N(R^7)(R^{7'})$, -C_1-C_6-alkyl-$C(=O)R^7$,-CN, $-C(=O)OR^7$, $-C(=O)N(R^7)(R^{7'})$, $-OR^7$, $-SR^7$, or $-NR^7C(=O)R^7$ each of which may be optionally substituted with 1 or more R^8 groups,
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same.


9. The compound according to claim 1 or claim 2, which is

N-(8-{[(2R)-2-Hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same.

10. The compound according to claim 1 or claim 2, which is
N-(8-{[(2R)-2-Hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide
or a physiologically acceptable salt, or a mixture of same.

11. The compound according to claim 1 or claim 2, which is
N-(8-{[(2R)-2-Hydroxy-3-(morpholin-4-yl)propyl]oxy}-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide.

12. A method of preparing a compound of general formula (I) according to any one of claims 1 to 11, said method comprising the step of allowing an intermediate compound of general formula (XI) :



(XI)


in which R1 and R3 are as defined for general formula (I) in any one of claims 1 to 11,

to react with a compound of general formula (XIa) :

R^2COOH

(XIa),

in which R2 is as defined for general formula (I) in any one of claims 1 to 11~~6~~, thereby giving a compound of general formula (I) :



(I)

in which R^1, R^2 and R^3 are as defined for general formula (I) in any one of claims 1 to 11.

13. A compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 11, for use in the treatment or prophylaxis of a disease.

14. A pharmaceutical composition comprising a compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 11, and a pharmaceutically acceptable diluent or carrier.

15. A pharmaceutical combination comprising :

- one or more compounds of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 11 ;

and


- one or more agents selected from : a taxane, such as Docetaxel, Paclitaxel, or Taxol; an epothilone, such as Ixabepilone, Patupilone, or Sagopilone; Mitoxantrone; Predinisolone; Dexamethasone; Estramustin; Vinblastin; Vincristin; Doxorubicin; Adriamycin; Idarubicin; Daunorubicin; Bleomycin; Etoposide; Cyclophosphamide; Ifosfamide; Procarbazine; Melphalan; 5-Fluorouracil; Capecitabine; Fludarabine; Cytarabine; Ara-C; 2-Chloro-2´-deoxyadenosine; Thioguanine; an anti-androgen, such as Flutamide, Cyproterone acetate, or Bicalutamide; Bortezomib; a platinum derivative, such as Cisplatin, or Carboplatin; Chlorambucil; Methotrexate; and Rituximab.

16. A compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 11, for use in therapy.

17. Use of a compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 11, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of uncontrolled cell growth, proliferation and/or survival, an inappropriate cellular immune response, or an inappropriate cellular inflammatory response, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is mediated by the phosphotidylinositol-3-kinase (PI3K) pathway, more particularly in which the disease of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is a haemotological tumour, a solid tumour and/or metastases thereof, *e.g.* leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung

tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.

18. A compound of general formula (XI) :



(XI)

in which R1 and R3 are as defined for general formula (I) in any one of claims 1 to 11.

19. Use of compounds of general formula (XI) according to claim 18, for the preparation of a compound of general formula (I) according to any one of claims 1 to 11.